BioTuesdays

Tag - H.C. Wainwright

Corvus Pharmaceuticals

HCW starts Corvus Pharma at buy; PT $10

H.C. Wainwright launched coverage of Corvus Pharmaceuticals (NASDAQ:CRVS) with a “buy” rating and $10 price target. The stock closed at $2.72 on March 9. Corvus is focused on developing precision medicines to treat...

ReWalk Robotics

HCW cuts ReWalk Robotics PT to $3.50 from $9

H.C. Wainwright lowered its price target for ReWalk Robotics (NASDAQ:RWLK) to $3.50 from $9, reflecting dilution from a recent public offering. The stock closed at 81 cents on Feb. 20. As a result of the financing, the...

Acasti Pharma

HCW halves Acasti Pharma PT to $3 from $6

H.C. Wainwright halved its price target for Acasti Pharma (NASDAQ:ACST) to $3 from $6 in light of the continued uncertainty around the company’s TRILOGY 1 and TRILOGY 2 trials. The stock closed at 57 cents on Feb. 14...

Iterum Therapeutics Logo

HCW cuts Iterum Therapeutics PT to $9 from $14

H.C. Wainwright lowered its price target for Iterum Therapeutics (NASDAQ:ITRM) to $9 from $14 after the company unveiled a $52-million private placement of exchangeable and royalty-linked subordinated notes earlier this...

Capricor Therapeutics

HCW lowers Capricor Therapeutics PT to $9

H.C. Wainwright lowered its price target for Capricor Therapeutics (NASDAQ:CAPR) to $9.50 based on a higher fully diluted share count but maintained its “buy” rating. The stock closed at $1.83 on Jan. 17. Analyst Joseph...

Mersana Therapeutics Logo

HCW ups Mersana Therapeutics PT to $12 from $7

H.C. Wainwright raised its price target for Mersana Therapeutics (NASDAQ:MRSN) to $12 from $7, saying the expected data flow, and available activity and safety profile bode well for the company’s XMT-1536 drug candidate...

Aduro Biotech

Analysts downgrade and lower PTs for Aduro Biotech

William Blair downgraded Aduro Biotech (NASDAQ:ADRO) to “market perform” from “outperform” and H.C. Wainwright cut its price target for Aduro after Novartis removed Aduro’s intratumoral STING agonist, ADU-S100, from its...

Diffusion Pharma Logo

HCW cuts Diffusion Pharma PT to $3.50 on dilution

H.C. Wainwright lowered its price target for Diffusion Pharmaceuticals (NASDAQ:DFFN) to $3.50 from $10, reflecting dilution from two recent financings. The stock closed at 41 cents on Dec. 17. Analyst Swayampakula...